BridgeMD
New treatment option for Depression
Official title Hybrid Type 1 Randomized Pilot Trial of a Peer-led Family and Social Strengthening Group Intervention for Refugee Families
ClinicalTrials.gov ID: NCT06261463
What this study is testing
- What it's testing
- The proposed study draws on prior research to evaluate the feasibility, acceptability and explore preliminary effectiveness of Coffee and Family Education and Support, Version (CAFES2) using a pilot randomized type 1 hybrid effectiveness-implementation design. CAFES2 is a peer-led family and social strengthening multiple family group intervention that is designed to respond to multi-level needs of refugee families.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 55
You may be able to join if
- To participate in the study, the families must meet the following criteria:
- Country of origin: Iraq, Syria, Lebanon, Jordan, Palestine or Yemen
- refugee family living in Chicago \< three years
- Contains at least one adult caregiver (18-55) and at least one of their children (age 12 and older) living in one household
- One family member with \> 3 on the GHQ-12
You likely can't join if
- for refugee families:
- Not from one of the following Arabic-speaking countries in the Middle East: Iraq, Syria, Jordan, Lebanon, Palestine, Yemen
- men and women who do not have least one child aged 12 years and older living in one household
- arrived in the U.S as a refugee greater than 3 years ago
- persons with developmental disabilities which would preclude their participation in the adapted CAFES intervention
- persons with severe mental health (e.g., suicidality psychotic disorder), active substance use or current in family crisis (e.g., domestic violence...
See the full eligibility criteria
- To participate in the study, the families must meet the following criteria:
- Country of origin: Iraq, Syria, Lebanon, Jordan, Palestine or Yemen
- refugee family living in Chicago \< three years
- Contains at least one adult caregiver (18-55) and at least one of their children (age 12 and older) living in one household
- One family member with \> 3 on the GHQ-12
- able to give written informed consent.
- for refugee families:
- Not from one of the following Arabic-speaking countries in the Middle East: Iraq, Syria, Jordan, Lebanon, Palestine, Yemen
- men and women who do not have least one child aged 12 years and older living in one household
- arrived in the U.S as a refugee greater than 3 years ago
- persons with developmental disabilities which would preclude their participation in the adapted CAFES intervention
- persons with severe mental health (e.g., suicidality psychotic disorder), active substance use or current in family crisis (e.g., domestic violence, divorce proceedings).
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.